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Abstract
Background: Psoriasis is an immune-mediated chronic inflammatory skin disorder for which several targeted biologic
therapies became available in the last 10 years. Data from patients with rheumatoid arthritis revealed that dose tapering
combined with tight control of disease activity is successful. For psoriasis patients the lowest effective dose of biologics
needs to be determined.
The objective was to assess whether dose tapering of biologics guided by Psoriasis Area and Severity Index (PASI) and
Dermatology Quality of Life Index (DLQI) scores in psoriasis patients with controlled disease activity is non-inferior (NI) to
usual care.
Methods/design: This is a multicenter, pragmatic, randomized, non-inferiority trial with cost- effectiveness
analysis. One hundred and twenty patients with stable low disease activity (PASI ≤ 5 and DLQI ≤ 5) for at least
6 months with a stable use of adalimumab, etanercept or ustekinumab will be randomized 1:1 to the dose reduction
group or usual care. In the dose reduction group, the treatment intervals will be prolonged stepwise, resulting in a 33%
and 50% dose reduction, respectively. Disease activity is monitored every three months with PASI and DLQI. In case of
flare the treatment is adjusted to the previous effective dose. The primary outcome (PASI) at 12 months will be analyzed
with ANCOVA in which the baseline PASI will be included as covariate to gain efficiency.
The secondary outcomes include number of and time to disease flares, health-related quality of life, serious adverse
events, and costs.
Discussion: With this study we want to assess whether disease activity guided dose reduction of biologics can be
achieved for psoriasis patients with low stable disease activity, without losing disease control. By using the lowest
effective dose of biologics, we expect to minimize side effects and save costs.
Trial registration: This trial was registered at ClinicalTrials.gov (NCT 02602925). Trial registration date October 9 2015.
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Background
Psoriasis is an immune-mediated chronic inflammatory
skin disorder, affecting 2–3% of the world population. It
is characterized by erythematous scaly plaques and associ-
ated with several significant comorbidities such as psoriatic
arthritis. Patients with moderate to severe psoriasis have a
high disease burden, the impairment of disease-related
quality of life is comparable to that of patients with
cancer and depression [1].
Several targeted biologic therapies have become avail-
able for psoriasis patients such as TNF-alpha inhibitors
(etanercept, adalimumab) and anti-IL-12/IL- 23 agents
(ustekinumab). These drugs block critical cytokine
pathways implicated in the pathophysiology of psoriasis.
Multiple trials have been conducted to study the safety
and efficacy of etanercept, adalimumab and ustekinumab
[2–4]. These biologics are widely used in daily practice.
Although, biologics are considered as relatively safe, side
effects do still occur, mainly due to immunosuppressive
effects. Especially in patients with chronic inflammatory
diseases such as psoriasis, where lifelong treatment is con-
sidered necessary to achieve disease control, it is import-
ant to minimize the chance of side effects. In addition,
biologic treatment is expensive and imposes a high burden
on the national health care expenditures [4, 5]. Lowering
the overall exposure to biologics could result in both a
lower risk of side effects and substantial health care
savings. We know from small studies that withdrawal
of the biologic showed quick disease recurrence in 99%
of patients with psoriasis [2, 3, 6–11]. Moreover, retreat-
ment with the biologic did not always reach the same
effectiveness as the first episode of treatment [8–10, 12].
Another option would be in patients with controlled dis-
ease to lower the dosage of biologics.
For psoriasis patients, there is lack of evidence of dose-
tapering of biologics and the lowest effective dose of bio-
logics in daily practice in the individual patient remains to
be determined. There is one poster reporting successful
dose tapering in 10 patients using adalimumab and a small
retrospective case series in which etanercept was tapered
has been published [13, 14]. Another cross-sectional study
described the retreatment after tapering of etanercept,
which was effective and well tolerated in psoriasis patients.
However, this study did not describe what the effect of
dose-tapering of etanercept was [9].
Recently, a disease activity guided dose tapering and
stopping strategy has been shown to be non- inferior to
treatment continuation in patients with rheumatoid arth-
ritis (RA) using adalimumab or etanercept [15]. However,
this evidence cannot directly be applied to patients with
psoriasis. Psoriasis is different disease with different genetic
background and different cytokines in the inflammatory
pathways are involved. This indicates differences regarding
drug related effectiveness, side-effects and behavioral factors.
For example, RA patients are treated in combination with
other disease-modifying anti rheumatic drugs, which may
influence the disease activity while dose-tapering of the
biologic. In psoriasis other biologics are used than in
RA and the biologic is mostly prescribed as monotherapy.
The biologic can also be combined with other co-
medication than in patients with RA.
In this study, we will focus on biologic dose-tapering
instead of withdrawal of the biologic. In daily practice,
the most widely used biologic treatments are adalimu-
mab, etanercept and ustekinumab.
Therefore, we designed a multicenter, randomized trial
to investigate whether clinical effectiveness of controlled
dose tapering is non-inferior the usual care with respect
to psoriasis activity for patients receiving adalimumab,
etanercept or ustekinumab.
Objectives
The aim of this study is to investigate whether tight con-
trolled dose reduction of biologics in patients with stable
plaque psoriasis and low disease activity in combination
with good dermatological quality of life is non-inferior
compared to therapy with the standard full dose. This
will lead us to the following research questions:
Primary objective
To assess whether a biologic dose tapering strategy in
psoriasis patients is non-inferior (NI) to usual care
measured by PASI at 12 months with a non-inferiority
margin of 0.5.
Secondary objectives
1. To assess the proportion of patients with successful
dose tapering at 12 months. We defined a successful
dose tapering as a lower dose than the regular dose
and PASI ≤ 5.
2. To compare the quality of life (Dermatology Quality
of Life index, DLQI) maintenance between the dose-
reduction group and usual care at month 3,6,9 and
12. If the difference at 12 months between the two
strategies is smaller than a NI margin of 2 we can
consider the strategies non-inferior regarding quality
of life.
3. To compare disease activity (PASI) at month 3,6,9
and 12 between the dose reduction group and usual
care.
4. To compare the proportion of patients with persistent
flares between the dose reduction group and usual care.
5. To identify factors which are associated with
successful dose-tapering. >The following factors will
be studied: baseline variables such as patient- disease
and treatment characteristics, CRP (C- Reactive
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protein), pharmacogenetic markers (HLA-C*06),
anti-drug antibody and trough levels.
6. To compare the occurrence of serious adverse events
(SAEs) between dose-reduction and usual care.
7. To calculate decremental cost-effectiveness of the
intervention compared to usual care.
Methods
Study setting
This study will be carried out in six departments of
dermatology in the Netherlands: one academic center
(Radboud University Medical Center, Nijmegen) and
five non-academic regional centers (St. Anna Hospital in
Geldrop, Ziekenhuisgroep Twente Almelo and Hengelo,
Gelre Hospital Apeldoorn and Slingeland Hospital
Doetinchem. Ethical approval for this study was obtained
from the Medical Ethical Committee (Arnhem- Nijmegen).
Written informed consent will be obtained from each
participant.
Eligibility
Patients who are diagnosed with plaque psoriasis and
have been using etanercept, adalimumab or ustekinumab
in a stable dose and have a sustained low disease activity
both for at least 6 months are eligible for this study. We
defined a sustained low disease activity as a PASI score ≤
5 for at least 6 months before inclusion (2 PASI scores
should available) and a DLQI ≤5 at moment of inclusion.
A PASI score ≤ 5 is chosen based on experts opinion and
it is in general accepted as low disease activity. A DLQI
score gives an indication of what the impact of psoriasis
is on the quality of life of these patients [16].
In order to establish whether a good disease control is
present, a combination of not only clinical outcome meas-
ure (PASI) but also a patient outcome measure (DLQI) is
assessed at baseline, month 3,6,9 and 12. Patients who are
eligible for this study must meet the following criteria:
Inclusion criteria
 Age ≥ 18 years.
 Diagnosis of plaque psoriasis established by a
dermatologist.
 Sustained low disease activity (PASI ≤ 5) for at least
6 months before inclusion and DLQI ≤ 5 at moment
of inclusion.
 Receiving stable and standard dosing treatment with
adalimumab, etanercept, or ustekinumab for at least
6 months
 Ability to understand informed consent, read and
answer questionnaires.
 All medication except for systemic
immunosuppressants other than methotrexate or
acitretine is allowed during the study.
Exclusion criteria
A potential subject who meets any of the following
criteria will be excluded from participation in this
study:
 Psoriasis not being the main reason for biologic
prescription (e.g. when a patient has RA and psoriasis,
and RA is the main reason for biologic use).
 Concomitant use of systemic immunosuppressants
other than methotrexate or acitretin for psoriasis.
Use of corticosteroid inhalations is permitted.
 When the biologic has been stopped for more than
4 weeks in the past 6 months.
 Severe comorbidities with short life-expectancy (e.g.
metastasized malignancy).
 Presumed inability to follow the study protocol.
Design
This is a multicenter, randomized non-inferiority trial
with a cost effectiveness analysis. This trial is currently
being conducted at the department of dermatology of
six medical centers. (see above in Study Setting) in the
Netherlands.
In this study a comparison will be made between an
intervention group (dose-tapering) and a group receiving
usual care. In the intervention arm we will reduce the
dose of the biologic by means of prolongation of the
intervals between two doses. We aim to determine
whether we can achieve the same clinical effect with
administration of a reduced dose of the biologic compared
to the standard full dose. Consequently, we chose for a
randomized controlled non-inferiority trial.
We aim to include patients on either adalimumab,
etanercept or ustekinumab to an equal extent. Inflixi-
mab was excluded as intermittent therapy increases
the risk for infusion reactions. No other biologics had
been approved at the moment of designing the study
and were therefore not included.
Recruitment
All patients who are eligible for this study will be asked
by their dermatologist and they will receive oral and
written information from the local investigator. The in-
vestigator will obtain written informed consent and the
patient will be randomized. The schedule of their bio-
logical will be explained depending on which biologic
the patient uses.
Subjects can leave the study at any time for any rea-
son if they wish to do so without any consequences.
The investigator can decide to withdraw a subject
from the study for urgent medical reasons. When sub-
jects are withdrawn from the study, they will not be
replaced.
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Randomization, blinding, treatment allocation
The investigator will generate the allocation sequence,
enroll patients and will assign participants to interven-
tions. Randomization of the subjects will be carried out
web-based with stratification by agent using variable
permuted blocks with concealment of allocation. Patients
will be randomized into 1:1 (1) dose- tapering strategy or
(2) drug continuation strategy of the standard dose of
adalimumab, etanercept or ustekinumab. Every three
months patients will be seen at the outpatient clinic
and the PASI and DLQI will be performed.
Patients in the dose-tapering group will receive adali-
mumab, etanercept or ustekinumab, and doses will be
lowered according to the schedule as described below.
Patients in the non dose-tapering group will receive the
standard dose without interval prolonging.
Study groups
Control group
Patients in the control group will continue the treatment
with the normal dose and treatment regimens will be
based on the prevailing guidelines. Treatment decisions
are made at the discretion of the treating dermatologist
following these guidelines. Control visits are planned
every three months and patients are explained to contact
their dermatologist when they experience increased disease
activity. The PASI, DLQI questionnaires and CRP are deter-
mined when patients visit their dermatologist. The research
physician will observe whether the dermatologist follows
the study protocol and will give advice when necessary. In
case of a disease flare treatment will be adjusted, topical
and systemic therapy will be optimized and when required
the dose of the biologic will be increased or treatment will
be switched to another agent.
Dose-tapering group
In the dose tapering group the doses of etanercept,
adalimumab or ustekinumab will be lowered according to a
predefined schedule. The intervals of drug-administration
will be prolonged stepwise depending on the PASI and
DLQI score. Dose-tapering is allowed when the PASI
score ≤5 and the DLQI score is ≤5. First, the dose will
be decreased to 66–70% of the normal dose of the biologic
(by interval prolongation with a factor 1.5). After 3 months,
if the patients remain in a state of low disease activity, the
dose will be further reduced to 50% of the original dose (by
doubling the original interval). This method of dose reduc-
tion is visualized in Fig. 1. The dose-reduction steps per
specific drug are as follows: For etanercept the interval will
be prolonged stepwise from 7 days to 10 days to 14 days.
For adalimumab, the interval will be prolonged from 14 to
21 to 28 days. For ustekinumab the interval will be stepwise
increased from 12 to 18 to 24 weeks. If possible, the patient
will stay on the lowest interval. When disease flare occurs,
confirmed by the dermatologist or research physician, the
patient will return to the previous effective dose interval.
When there is still no disease control after reintroduction
of the normal dose, treatment will be adjusted: topical and
systemic therapy will be optimized and when required the
dose of the biologic will be increased or treatment will be
switched to another agent.
Procedures and outcome measures
At baseline the patient and treatment characteristics will
be measured and collected, such as sex, age, previous
conventional antipsoriatic drugs and/or biologics used,
disease duration, PASI and DLQI scores. Baseline measures
will also be extracted from the existing BioCAPTURE data-
base and will be used for identifying predictors for success-
ful dose tapering. The BioCapture database is a prospective
cohort of patients with psoriasis using biologicals in daily
practice [17]. Genetic factors or polymorphisms influencing
response on biologicals, such as HLA-C*6, may be related
to successful dose-tapering and will also be measured [18].
Blood samples will be drawn for safety, genetic analysis,
determining antibodies and trough levels. Patients will be
followed for 1 year and regular visits will be planned at
baseline, month 3,6,9 and 12. Every visit the PASI and
DLQI score, CRP, anti- drug antibody, trough levels,
disease flares, costs, health status, questionnaires, Severe
Adverse Events (SAE) and their causal relation with the
biologic will be determined. Patients with a disease flare will
be seen within a week and additional visits or telephone
contact will be planned within 2 or 4 weeks.
Our primary outcome measure is disease activity (PASI)
at 12 months and will be analyzed with ANCOVA in which
the baseline PASI will be included as covariate to gain effi-
ciency. If the lower limit of the 95% confidence interval
around the mean difference in PASI score between the
intervention group and control group does not exceeds the
non- inferiority margin (−0.5) at 12 months of follow up,
the intervention can be regarded as non-inferior to usual
practice.
Our secondary study outcome measures are as follows:
the DLQI, the number of patients with 1 or more per-
sistent flares (defined as having at least 3 months PASI
score >5 or DLQI > 5), treatment characteristics (dose of
the biologic, drug pauses, use of concomitant antipsoria-
tic systemic drugs, use of topical therapies), CRP, anti-
drug antibodies and trough levels, SAE and their causal
relation with the biologic, costs questionnaires and
health status.
Definition of (persistent) disease flare
A (short) psoriasis flare in this study is defined as a PASI
score > 5 and/or DLQI score > 5, a persistent flare is de-
fined as a PASI score > 5 and/or the DLQI score >5 for
at least 3 months. DLQI ≤ 5 means mild influence on
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quality of life and is part of the published treatment
goals [6, 19, 20]. Zweegers et al. showed that the mean
PASI of patients that remain on a biologic is ≤ 5 [21].
Moreover, PASI ≤ 5 is associated with low DLQI scores
[22]. Therefore we think that PASI ≤5 is a good thresh-
old for minimal disease activity in general. In the excep-
tional case were PASI 5 still represents relatively active
disease, DLQI score is expected to be high and patients
will still be classified as having a flare.
Power and sample size analyses
We estimated that per arm 54 patients should be in-
cluded to provide sufficient power for statistical analyses
(P 80%). The non-inferiority (NI) margin of 0.5 was
based on our opinion of clinical meaningfulness. Also, as
patients in clinical remission in the BioCAPTURE co-
hort showed a PASI standard deviation (SD) of 1.4, the
margin of 0.5 is 36% of the SD. This percentage approxi-
mates a rule of thumb for calculating the non-inferiority
margin: 1/3 of SD. As we will perform our analysis with
correction for the baseline value of PASI, a formula that
will increase power significantly is available taking into
account the correlation between the baseline value and
the follow-up measurements [23]. This correlation was
found to be a 0.67 in our existing cohort. When per-
forming a t-test for sample size calculation, the sample
size can be multiplied by 1- ρ2 if we add one extra sub-
ject per group, where ρ is the correlation between the
baseline measure and the follow-up measure here (0.67).
Thus when we perform an ANCOVA analysis correcting
for baseline PASI with the non-inferiority margin set at
0.5, α set at 5% and a ρ of 0.67, we achieve 80% power
when enrolling 54 patients per arm. Taking a possible
drop-out rate of 10% into account, 60 patients need to
be included in each arm.
Data collection and management
All data will be collected and entered in CASTOR. This is
an electronic data management system which is setup for
clinical trials [24]. Data will be coded and kept based on
Fig. 1 Patients using adalimumab, etanercept or ustekinumab will be randomized to dose tapering or usual care. Control visits will be planned
every 3 months for the assessments of PASI, DLQI, cost-effectiveness questionnaires, drug levels and anti-drug antibodies (at trough moment).
Ustekinumab blood samples for immunologic analyses are taken at deviating time points (trough moments) due to the low frequency of injections.
CEQ = Cost-effectiveness questionnaires (SF-36, iMTA Medical Consumption Questionnaire and productivity cost questionnaire), PASI = Psoriasis Area
and Severity Index, DLQI = Dermatology Quality of Life
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the rules for good clinical practice (GCP) by GCP certified
personnel [25]. Handling of personal data will comply
with the Dutch Personal Data Protection Act [26].
All blood samples will be coded before sending to the
dermatology laboratory at the Radboudumc and Sanquin
where the samples will be analyzed. Blood for pharmacoge-
netic investigations will also be coded before work-up in
the genetic department of the Radboudumc.
Statistical analysis
Per protocol analyses will be performed as a primary
method for the most outcomes as this is preferred and
most conservative analysis for non-inferiority studies
[27]. Lost to follow up subjects will be incorporated until
their lost to follow up date only, as it is a per protocol
approach. However, for the cost-effectiveness analysis an
intention- to- treat analysis will be performed separately.
Extent and nature of missing data and information about
lost to follow up subjects will be described. For the
intention-to-treat analysis a lost observation carried
forward approach will be used for those that were lost
to follow up. In case of missing data for patients that
did complete the follow-up imputation of missing data
will be performed.
The primary study outcome (PASI at 12 months) will
be analyzed with ANCOVA. The baseline PASI will also
be included as a covariate to gain efficiency. The proportion
of patients with successful dose tapering will be assessed.
The DLQI and PASI scores, antidrug antibodies and trough
levels will be directly compared at time points month 3,6,9
and 12 between the two groups using an unpaired t-test or
a non- parametric alternative. The DLQI will be formally
tested on non-inferiority. If the upper limit of the 95% con-
fidence interval of the difference between the two strategies
lower than the NI margin of 2, we can consider the strat-
egies non-inferior regarding quality of life. This NI margin
of 2 is approximately a 1/3 of the standard deviation (data
on file) which complies with a general rule of thumb for
determining a NI margin. Furthermore, a difference in
DLQI larger than 2 can be considered as clinically rele-
vant. The number of persistent flares for both groups
will be analyzed as rate ratios and relative ratios with
some confidence intervals. With Kaplan-Meier curves
the time until flare for dose tapering will be presented. All
SAEs will be described per group in a frequency table.
Thereafter, cost effectiveness analyses will be calculated
based on the questionnaires medical consumption, prod-
uctivity costs and health status (SF-36). Because we antici-
pate non-inferiority we will primarily analyze cost-savings:
direct medical cost as well as total costs (medical and non-
medical costs) will be compared between dose tapering
strategy and usual care. A possible small but acceptable loss
of effect can be incorporated in the analyses by determining
a decremental cost-effectiveness ratio (DCER) by dividing
the difference in costs by the difference in Quality Adjusted
Life Years (QALYs) between the groups. The DCER
expresses with how much money a loss of 1 QALY is
compensated. If this amount is high, the decision
makers are willing to accept a loss of effect. Further-
more, the Net Monetary Benefit (NMB) per patient
will be calculated for different levels of willingness to
pay (WTP) in dollars per QALY, using the formula:
WTP * effect (difference in QALY) - costs. This results
in the net amount of money saved, when the possible
loss of QALY is corrected for, using different WTP
levels per QALY.
Immunological analyses
Immunologic analyses will be done for each biologic to
determine anti-drug antibodies/trough level and logistic
regression analyses will be carried out to identify predictors
that are related to the absence of flare. The four most
promising variables will be tested.
Monitoring
Data of all centers will be monitored following the
guidelines of the Radboudumc. The research nurse of
the Radboudumc will monitor all centers involved in this
study.
Discussion
Without doubt biologics represent a very effective modality
to treat patients with moderate to severe psoriasis. Dose-
reduction of biologics while maintaining clinical effective-
ness is a promising way to improve safety and reduce the
costs of this type of therapy. The relatively short follow up
time could be considered as a limitation. For this reason we
will follow patients during 1 year after the end of this initial
study. This will lead to insight in the long-term effects of
dose reduction. Successful dose-reduction of adalimumab
and etanercept has been demonstrated in patients with RA
[15], however there are only limited data for patients with
psoriasis. In this prospective randomized non- inferiority
study the possibility will be investigated of dose-reduction
of the most used biologics for psoriasis: adalimumab,
etanercept and ustekinumab. If dose-reduction is non-
inferior to the current care with standard dosages, we can
treat patients with lower dosages of biologics in daily prac-
tice. This can lead to a lower risk of side effects and re-
duce health care costs.
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